Malignant peritoneal neoplasm+2
Not yet recruitingA Phase 3 Study of Raludotatug Deruxtecan With or Without Bevacizumab as Maintenance Therapy in Patients With Platinum‑Sensitive Recurrent Ovarian Cancer
A Phase 3 Study of Raludotatug Deruxtecan With or Without Bevacizumab as Maintenance Therapy in Patients With Platinum‑Sensitive Recurrent Ovarian Cancer
- Disease:Malignant peritoneal neoplasmFallopian tube cancer+1
- Substances:BevacizumabRaludotatug Deruxtecan
Italy- Participants:18–64 years · 65+ years
- Substances:Bevacizumab
- Sponsor:Daiichi Sankyo Inc.












